Our Insights Oncology Anthony Iannacci 11/3/26 Oncology Anthony Iannacci 11/3/26 Pfizer’s Xtandi + Talzenna Combo Approved in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Scoring a Much Broader Label Than J&J’s Akeega Read More Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More Oncology Anthony Iannacci 6/11/26 Oncology Anthony Iannacci 6/11/26 TP53, the most altered gene in oncology Read More Oncology Anthony Iannacci 4/7/26 Oncology Anthony Iannacci 4/7/26 Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality Read More Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More Want to get in touch? Click here
Oncology Anthony Iannacci 11/3/26 Oncology Anthony Iannacci 11/3/26 Pfizer’s Xtandi + Talzenna Combo Approved in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Scoring a Much Broader Label Than J&J’s Akeega Read More
Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More
Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More
Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More
Oncology Anthony Iannacci 6/11/26 Oncology Anthony Iannacci 6/11/26 TP53, the most altered gene in oncology Read More
Oncology Anthony Iannacci 4/7/26 Oncology Anthony Iannacci 4/7/26 Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality Read More
Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More